Phase 2 N=65 A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)
Childhood-Onset Fluency Disorder
Primary: Change From Baseline to End of 6 Weeks in Total MLGSSS — -7.0; -5.5 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=71 A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Neuroendocrine Neoplasms
Primary: Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants) — 40; 6 Participants
N/A N=80 Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals With Self-Perceived Thinning Hair
Hair Thinning
Primary: Hair Shedding (1-2 Hairs Per Unit) — 21; 10 Participants
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
Phase 2 N=1 JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
Kohlmeier Degos Disease With Neurologic Involvement · Kohlmeier-Degos Disease
Primary: Number of Participants With Stable or no Lesions Developed Based on MRI Neurological Involvement of K-D Disease Following Ruloxitinib — 1; 0; 0 Participants
N/A N=79 Empowering Patients' Lung Cancer Screening Uptake
Lung Cancer
Primary: Order of LDCT — 50 Participants
N/A N=70 Sleep Treatment Education Program-1 (STEP-1)
Cancer Survivors · Insomnia
Primary: Insomnia Severity Change at 8 Weeks — 7.3; 9.5 Units on a scale
Phase 2 N=12 Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Fibrous Dysplasia Of Bone
Primary: Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 — 1 Proportion of participant
Phase 2 N=26 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Human Immunodeficiency Virus 1 Positive · Skin Kaposi Sarcoma
Primary: Overall Response Rate — 0.577 proportion of participants
N/A N=14 An Investigation on Function and Performance of a New Microprocessor Controlled Prosthetic Knee
Prosthesis User · Amputation
Primary: Satisfaction During Stair Descent — 0.80 score on a scale
N/A N=30 Feasibility of Measuring Volume of Inspiration Via Noninvasive Motion Sensors
Postoperative Pulmonary Complications (PPCs)
Primary: Participants With Collectable Waveform Data — 30 Participants
Phase 1 N=25 Effects of Commonly Used Medications on Mood and Choice
Healthy
Primary: Participant Subjective Ratings of Drug Liking (Peak Change) — 1.00; -0.11; 0.88; 0.33 score on a scale
N/A N=205 Screen to Save 2: Rural Cancer Screening Educational Intervention
Cancer · Colorectal Cancer
Primary: Change in Correct Responses Regarding Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening — -.5; 0; 1; 2 Percent Change — p=<.0001
N/A N=100 Acute Coronary Syndrome KCMC_1
Hypertension · HIV
Primary: Feasibility as Measured by the Number of Total Scheduled Intervention Sessions (CHW Counseling Sessions, Doctor's Visits, Phone Calls) Attended — 589 Scheduled sessions
Phase 4 N=20 Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Trigeminal Neuralgia · Glossopharyngeal Neuralgia
Primary: Change in Pain Score — -0.6224; -1.005; -0.8102; -1.079 score on a scale